Biocon-Viatris Biosimilars Combine: Deal Or No Deal?
Executive Summary
Are Viatris and long-standing partner Biocon mulling a consolidation of their biosimilars business? Some analysts suggest any deal that positions Viatris as a minority stakeholder in a potential combine doesn’t bode well for the US firm.
You may also be interested in...
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.
Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’
Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.
Viatris Pushes Back ‘Roadmap’ Reveal
Viatris has delayed the big reveal of details of its two-phase strategic roadmap that had been due to take place at an investor event planned for early January.